Advertisement
Advertisement
U.S. markets close in 2 hours 27 minutes
Advertisement
Advertisement
Advertisement
Advertisement

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
19.68+1.67 (+9.27%)
As of 01:32PM EDT. Market open.
Advertisement
Sign in to post a message.
  • M
    Mason
    Good earnings. I've seen new paper with results from their second gen vaccine. Its multivalent and cross neutralizing all covid variants. Hope it will be publicated soon. Hope GSK collaboration will make the approval fast!
    Bullish
  • M
    Mike
    Why not reach 20$ before the end of the week! We only need one good news! 🤟
    Bullish
  • O
    Owen
    Curevac vaccine is the future! Moderna, Pfizer and novavax are all dead. Only Curevac new vaccine works against all covid variants!
    Bullish
  • L
    Logan
    Only Curevac is UP because Curevac is the FUTURE!!! Vaccine against all covid variants!
    Bullish
  • s
    samirb
    hope to see 150#$%$ soon
    Bullish
  • J
    Jason
    Monday we GO UP
    Bullish
  • J
    Jason
    Does anyone know when sec gen phase 1/2 results? Should be soon, should be great.
    Bullish
  • b
    bloodyman
    (ZYNE) $1.60 ...Heavy underpriced Cannabis Play with Blockbuster Pipeline near data readout=1000%+ UPSIDE
    https://assets.wallstreet-online.de/_media/8763/board/20220328161124-screenshot-2022-03-28-at-16-10-45-powerpoint-pres.png

    #++#+
  • L
    Logan
    Curevac vaccine is the future! Moderna, Pfizer and novavax are all dead. Only Curevac new vaccine works against all covid variants.
    Bullish
  • J
    Johnny7321..923
    There are so many products in pipe like, looks like they want to be Amazon of cures but they don’t have any cure yet. It cost $2 billion and 2 years trial before FDA can approve anything. Their goal is not realistic. Sorry Bill Gates, you should stick with making a better computer.
  • Y
    Yahoo Finance Insights
    CureVac is up 8.24% to 17.33
  • Y
    Yahoo Finance Insights
    CureVac is up 9.14% to 18.03
  • E
    Eye
    BioNTech, CureVac part of $3.14B deal to bolster German vaccine capacity through 2029: report
    Homegrown mRNA players BioNTech and CureVac have signed on to supply Germany with vaccines against future health emergencies for years to come.

    Germany will pay upward of 2.86 billion euros ($3.14 billion) to lock up local vaccine production capacity through 2029, Reuters reports, citing the country’s economy ministry. Wednesday, the German government approved plans to sign contracts with mRNA specialist BioNTech plus the partnership between CureVac and GlaxoSmithKline. Also involved are contract manufacturers Wacker, CordenPharma, Celonic and IDT, the news outlet said.
  • b
    bert
    it will soon on positive way if EUA and FDA green light gift.
  • b
    bert
    time to buy all what you can now?!!!
  • B
    Bal ch
    The EU Commission has signed a contract with the Tübingen-based company Curevac for the purchase of up to 405 million doses of corona vaccine.
  • G
    Gino
    My take on today's fall: CVAC is not a cheap stock and after a few days worth of reasonable gains there will be instant downward pressure. There are a lot of retail investors in this stock too. This will attract a degree of day traders possibly short selling and spooking longs to make a quick buck. But the fundamentals have NOT changed. And the information we get from CVAC and elsewhere is only positive. Regarding variants CVAC has already done lab tests on the SA variant and results were excellent. I see no good reason to sell, I'd buy more if I could.
  • E
    Entrepreneur Germany
    Please help: Why CureVac is going that much up without having a product on the street.
  • G
    Gino
    published today, a new interview with Kremsner. Two key quotes: "he expects data that are similar to those of other mRNA vaccines" + “It looks good,” says the Austrian Kremsner on the phone. The crucial phase III study should be completed “soon”, probably in May. + "Curevac predicts that the current problems with the supply of raw materials and equipment from the USA will not reduce production volumes this year." + “We are therefore reaffirming our production forecast of 300 million doses of our vaccine candidate CVnCoV in 2021,” explains a company spokeswoman.
  • O
    Ole
    Sadly, most people are focused on the primary efficacy numbers which is prevention of infection. There are other endpoints to measure efficacy such as prevention of severe illness/hospitalization and prevention of death. So far most of the vaccines in use have shown >80% and >90% efficacy for these endpoints. I believe CVAC will also show this level of protection. Most people don't understand how vaccines work. Yes, the best is to prevent infection by having a high titre of neutralizing antibodies in the bloodstream to prevent the virus from infecting cells. But even if the level is below the threshold due to partial variant escape the next levels of vaccine-induced immunity are met so if you do get infected the symptoms are mild and only last a few days as your immunological memory, created by the vaccine, work quickly to eliminate the virus very efficiently. You don't get severely ill and you don't die. So, even if the primary efficacy of prevention of infection is let's say below 80% the next 2 markers of efficacy will be met. If PFE, MRNA, AZ, JJ were tested in the same environment they too would give similar results.
Advertisement
Advertisement